TY - JOUR
T1 - Evaluating efficacy of aflibercept in refractory exudative age-related macular degeneration with OCT segmentation volumetric analysis
AU - Choi, Catherine S.
AU - Zhang, Li
AU - Abràmoff, Michael D.
AU - Sonka, Milan
AU - Shifera, Amde Selassie
AU - Kay, Christine N.
N1 - Funding Information:
Supported in part by a grant from Foundation Fighting Blindness (PI: Christine Kay); Arnold and Mabel Beckman Initiative for Macular Research, (PI: Abràmoff); and National Institutes for Health R01-EY017066 and R01-EY018853 (PI: Abràmoff and Sonka) and R01-EB004640 EY018853 (PI: Sonka).
Publisher Copyright:
© 2016, Slack Incorporated. All rights reserved.
PY - 2016/3
Y1 - 2016/3
N2 - BACKGROUND AND OBJECTIVE: To use automated segmentation software to analyze spectral-domain optical coherence tomography (SD-OCT) scans and evaluate the effectiveness of aflibercept (Eylea; Regeneron, Tarrytown, NY) in the treatment of patients with exudative age-related macular degeneration (AMD) refractory to other treatments. PATIENTS AND METHODS: Retrospective chart review of 16 patients refractory to bevacizumab (Avastin; Genentech, South San Francisco, CA)/ranibizumab (Lucentis; Genentech, San Francisco, CA) treatment was conducted. Visual acuity, central foveal thickness (CFT), maximum fluid height, pigment epithelial detachment (PED) volume, subretinal fluid (SRF) volume, fluid-free time interval, and adverse effects were evaluated. Automated segmentation analysis was used to quantify improvement. RESULTS: With aflibercept treatment, there was a statistically significant improvement in visual acuity by 1 line (P = .020), in CFT by 74.02 μm (P = .001), and in maximum fluid height by 31.9 μm (P= .011). Total PED and SRF volume also decreased significantly by 1.50 μm3 x 108 μm3 (P = .013). Anatomic improvement was confirmed by automated segmentation analysis. CONCLUSION: This study demonstrates utility of automated segmentation software in quantifying anatomic improvement with aflibercept treatment in exudative AMD refractory to other anti-vascular endothelial growth factor treatments.
AB - BACKGROUND AND OBJECTIVE: To use automated segmentation software to analyze spectral-domain optical coherence tomography (SD-OCT) scans and evaluate the effectiveness of aflibercept (Eylea; Regeneron, Tarrytown, NY) in the treatment of patients with exudative age-related macular degeneration (AMD) refractory to other treatments. PATIENTS AND METHODS: Retrospective chart review of 16 patients refractory to bevacizumab (Avastin; Genentech, South San Francisco, CA)/ranibizumab (Lucentis; Genentech, San Francisco, CA) treatment was conducted. Visual acuity, central foveal thickness (CFT), maximum fluid height, pigment epithelial detachment (PED) volume, subretinal fluid (SRF) volume, fluid-free time interval, and adverse effects were evaluated. Automated segmentation analysis was used to quantify improvement. RESULTS: With aflibercept treatment, there was a statistically significant improvement in visual acuity by 1 line (P = .020), in CFT by 74.02 μm (P = .001), and in maximum fluid height by 31.9 μm (P= .011). Total PED and SRF volume also decreased significantly by 1.50 μm3 x 108 μm3 (P = .013). Anatomic improvement was confirmed by automated segmentation analysis. CONCLUSION: This study demonstrates utility of automated segmentation software in quantifying anatomic improvement with aflibercept treatment in exudative AMD refractory to other anti-vascular endothelial growth factor treatments.
UR - http://www.scopus.com/inward/record.url?scp=84983784525&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983784525&partnerID=8YFLogxK
U2 - 10.3928/23258160-20160229-07
DO - 10.3928/23258160-20160229-07
M3 - Article
C2 - 26985798
AN - SCOPUS:84983784525
SN - 2325-8160
VL - 47
SP - 245
EP - 251
JO - Ophthalmic Surgery and Lasers
JF - Ophthalmic Surgery and Lasers
IS - 3
ER -